Exagen Inc Stock Analysis
XGN Stock | USD 1.56 0.02 1.30% |
Exagen Inc is undervalued with Real Value of 2.69 and Target Price of 6.25. The main objective of Exagen stock analysis is to determine its intrinsic value, which is an estimate of what Exagen Inc is worth, separate from its market price. There are two main types of Exagen's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Exagen's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Exagen's stock to identify patterns and trends that may indicate its future price movements.
The Exagen stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Exagen is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Exagen Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Exagen's ongoing operational relationships across important fundamental and technical indicators.
Exagen |
Exagen Stock Analysis Notes
About 30.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.18. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Exagen Inc recorded a loss per share of 1.34. The entity had not issued any dividends in recent years. Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Exagen operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 219 people. For more information please call John Aballi at 760 560 1501 or visit https://www.exagen.com.Exagen Quarterly Total Revenue |
|
Exagen Inc Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Exagen's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Exagen Inc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Exagen Inc generated a negative expected return over the last 90 days | |
Exagen Inc has high historical volatility and very poor performance | |
Exagen Inc may become a speculative penny stock | |
Exagen Inc has a very high chance of going through financial distress in the upcoming years | |
The company reported the last year's revenue of 52.55 M. Reported Net Loss for the year was (23.69 M) with profit before taxes, overhead, and interest of 21.35 M. | |
Exagen Inc has about 76.39 M in cash with (14.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Exagen Inc has a frail financial position based on the latest SEC disclosures | |
Roughly 60.0% of the company outstanding shares are owned by institutional investors | |
Latest headline from simplywall.st: Why Investors Shouldnt Be Surprised By Exagen Inc.s 31 percent Share Price Plunge |
Exagen Inc Upcoming and Recent Events
Earnings reports are used by Exagen to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Exagen previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
18th of March 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
18th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Exagen Largest EPS Surprises
Earnings surprises can significantly impact Exagen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2020-05-11 | 2020-03-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2021-08-09 | 2021-06-30 | -0.44 | -0.38 | 0.06 | 13 | ||
2022-03-22 | 2021-12-31 | -0.5 | -0.42 | 0.08 | 16 |
Exagen Thematic Classifications
In addition to having Exagen stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
HealthcareUSA Equities from Healthcare industry as classified by Fama & French |
Exagen Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Exagen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exagen Inc backward and forwards among themselves. Exagen's institutional investor refers to the entity that pools money to purchase Exagen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Penbrook Management Llc | 2023-09-30 | 73.4 K | Blackrock Inc | 2023-09-30 | 67.1 K | Dimensional Fund Advisors, Inc. | 2023-09-30 | 54.4 K | Bridgeway Capital Management, Llc | 2023-09-30 | 40.8 K | State Street Corporation | 2023-09-30 | 33.7 K | Millennium Management Llc | 2023-09-30 | 31.2 K | Northern Trust Corp | 2023-09-30 | 16.4 K | First Bank & Trust (brookings Sd) | 2023-12-31 | 13.5 K | Prudential Financial Inc | 2023-09-30 | 10.6 K | Rtw Investments, Llc | 2023-09-30 | 1.5 M | Stonepine Capital Management Llc | 2023-09-30 | 1.2 M |
Exagen Market Capitalization
The company currently falls under 'Micro-Cap' category with a total capitalization of 26.37 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Exagen's market, we take the total number of its shares issued and multiply it by Exagen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Exagen Profitablity
Exagen's profitability indicators refer to fundamental financial ratios that showcase Exagen's ability to generate income relative to its revenue or operating costs. If, let's say, Exagen is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Exagen's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Exagen's profitability requires more research than a typical breakdown of Exagen's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of (0.45) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.37) %, which entails that for every $100 of revenue, it lost $0.37. Last Reported | Projected for 2024 | ||
Return On Capital Employed | (0.51) | (0.53) | |
Return On Assets | (0.42) | (0.44) | |
Return On Equity | (1.04) | (1.10) |
Management Efficiency
Exagen Inc has Return on Asset of (0.1994) % which means that on every $100 spent on assets, it lost $0.1994. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7272) %, meaning that it generated no profit with money invested by stockholders. Exagen's management efficiency ratios could be used to measure how well Exagen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to drop to -0.53. In addition to that, Return On Assets is likely to drop to -0.44. At this time, Exagen's Fixed Asset Turnover is very stable compared to the past year.Last Reported | Projected for 2024 | ||
Price Book Value Ratio | 1.55 | 0.88 | |
Enterprise Value Multiple | (1.08) | (1.14) | |
Price Fair Value | 1.55 | 0.88 |
The analysis of Exagen's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Exagen's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Exagen Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.229 |
Technical Drivers
As of the 28th of March, Exagen shows the Coefficient Of Variation of (9,363), standard deviation of 5.61, and Mean Deviation of 3.76. In respect to fundamental indicators, the technical analysis model provides you with a way to check existing technical drivers of Exagen, as well as the relationship between them. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Exagen Inc, which can be compared to its rivals. Please confirm Exagen Inc mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Exagen Inc is priced favorably, providing market reflects its regular price of 1.56 per share. Please also check Exagen Inc jensen alpha, which is currently at (0.13) to verify the company can sustain itself at a future point.Exagen Inc Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Exagen middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Exagen Inc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Exagen Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exagen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exagen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exagen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adawi Kamal over three weeks ago Disposition of 3487 shares by Adawi Kamal of Exagen at 1.9099 subject to Rule 16b-3 | ||
John Aballi over a month ago Acquisition by John Aballi of 175000 shares of Exagen subject to Rule 16b-3 | ||
Tullis James L L over six months ago Exagen exotic insider transaction detected | ||
Tullis James L L over six months ago Purchase by Tullis James L L of 167 shares of Exagen |
Exagen Predictive Daily Indicators
Exagen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Exagen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Exagen Forecast Models
Exagen's time-series forecasting models are one of many Exagen's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Exagen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Exagen Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Exagen prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Exagen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Exagen. By using and applying Exagen Stock analysis, traders can create a robust methodology for identifying Exagen entry and exit points for their positions.
Last Reported | Projected for 2024 | ||
Pretax Profit Margin | (0.45) | (0.47) | |
Operating Profit Margin | (0.43) | (0.46) | |
Net Loss | (0.45) | (0.47) | |
Gross Profit Margin | 0.56 | 0.59 |
Current Exagen Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Exagen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Exagen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
6.25 | Strong Buy | 6 | Odds |
Most Exagen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Exagen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Exagen Inc, talking to its executives and customers, or listening to Exagen conference calls.
Exagen Stock Analysis Indicators
Exagen Inc stock analysis indicators help investors evaluate how Exagen stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Exagen shares will generate the highest return on investment. By understating and applying Exagen stock analysis, traders can identify Exagen position entry and exit signals to maximize returns.
Begin Period Cash Flow | 62.4 M | |
Long Term Debt | 19.2 M | |
Common Stock Shares Outstanding | 17.7 M | |
Total Stockholder Equity | 22.7 M | |
Tax Provision | 33 K | |
Property Plant And Equipment Net | 8.5 M | |
Cash And Short Term Investments | 36.5 M | |
Cash | 36.5 M | |
Accounts Payable | 3.1 M | |
Net Debt | -12.8 M | |
50 Day M A | 1.9524 | |
Total Current Liabilities | 11.9 M | |
Other Operating Expenses | 75.4 M | |
Non Current Assets Total | 9.1 M | |
Non Currrent Assets Other | 416 K | |
Stock Based Compensation | 3.6 M |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Exagen Inc information on this page should be used as a complementary analysis to other Exagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Exagen Stock analysis
When running Exagen's price analysis, check to measure Exagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exagen is operating at the current time. Most of Exagen's value examination focuses on studying past and present price action to predict the probability of Exagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exagen's price. Additionally, you may evaluate how the addition of Exagen to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Exagen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Revenue Per Share 2.972 | Quarterly Revenue Growth 0.072 | Return On Assets (0.20) | Return On Equity (0.73) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.